(Q43719397)

26 November 2017

Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring (English)

1 reference

26 November 2017

D Layton

1

1 reference

26 November 2017

G L Pearce

series ordinal

2

1 reference

26 November 2017

S A Shakir

series ordinal

3

1 reference

26 November 2017

1 January 2001

1 reference

26 November 2017

1 reference

26 November 2017

24

1 reference

26 November 2017

9

1 reference

26 November 2017

703-713

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200124090-00005

26 November 2017

0 references

cites work

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder

1 reference

12 December 2020

A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies

1 reference

12 December 2020

Terodiline. A review of its pharmacological properties, and therapeutic use in the treatment of urinary incontinence

1 reference

12 December 2020

Prescription-event and other forms of epidemiological monitoring of side-effects in the UK

1 reference

12 December 2020

Terminology in prescription-event monitoring

1 reference

12 December 2020

Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data

1 reference

12 December 2020

Muscarinic receptor antagonists in the treatment of overactive bladder

1 reference

12 December 2020

Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study

1 reference

12 December 2020

10.2165/00002018-200124090-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

26 November 2017

0 references

1 reference